Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chio Yokose

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
BMJ (Clinical Research Ed.)|October 30, 2024
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studiesNatalie McCormick, Chio Yokose, Na Lu, et al.
Arthritis Care & Research|August 22, 2024
Prediagnostic Amino Acid Metabolites and Risk of Gout, Accounting for Serum Urate: Prospective Cohort Study and Mendelian RandomizationNatalie McCormick, Amit D Joshi, Chio Yokose, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 13, 2022
Interactions Between Genetic Risk and Diet Influencing Risk of Incident Female Gout: Discovery and Replication Analysis of Four Prospective CohortsKehuan Lin, Natalie McCormick, Chio Yokose, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 26, 2025
Comparative Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drug Versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients With Gout: Target Trial EmulationsChio Yokose, Natalie McCormick, Na Lu, et al.
Seminars in Arthritis and Rheumatism|April 24, 2024
Serum urate change among gout patients treated with sodium-glucose cotransporter type 2 inhibitors vs. sulfonylurea: A comparative effectiveness analysisChio Yokose, Greg Challener, Bohang Jiang, et al.
ACR Open Rheumatology|March 24, 2025
The Design of a Randomized Controlled Active Comparator Strategy Trial for Gout: Treat to Target Serum Urate Versus Treat to Avoid SymptomsDaniel H Solomon, Misti Paudel, Shravani Chitineni, et al.
Arthritis Care & Research|May 11, 2021
Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item ReductionSara K Tedeschi, Tristan Pascart, Augustin Latourte, et al.
Annals of the Rheumatic Diseases|July 26, 2023
The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition diseaseAbhishek Abhishek, Sara K Tedeschi, Tristan Pascart, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 26, 2023
The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition DiseaseAbhishek Abhishek, Sara K Tedeschi, Tristan Pascart, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
BMJ (Clinical Research Ed.)|October 30, 2024
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studiesNatalie McCormick, Chio Yokose, Na Lu, et al.
Arthritis Care & Research|August 22, 2024
Prediagnostic Amino Acid Metabolites and Risk of Gout, Accounting for Serum Urate: Prospective Cohort Study and Mendelian RandomizationNatalie McCormick, Amit D Joshi, Chio Yokose, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 13, 2022
Interactions Between Genetic Risk and Diet Influencing Risk of Incident Female Gout: Discovery and Replication Analysis of Four Prospective CohortsKehuan Lin, Natalie McCormick, Chio Yokose, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 26, 2025
Comparative Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drug Versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients With Gout: Target Trial EmulationsChio Yokose, Natalie McCormick, Na Lu, et al.
Seminars in Arthritis and Rheumatism|April 24, 2024
Serum urate change among gout patients treated with sodium-glucose cotransporter type 2 inhibitors vs. sulfonylurea: A comparative effectiveness analysisChio Yokose, Greg Challener, Bohang Jiang, et al.
ACR Open Rheumatology|March 24, 2025
The Design of a Randomized Controlled Active Comparator Strategy Trial for Gout: Treat to Target Serum Urate Versus Treat to Avoid SymptomsDaniel H Solomon, Misti Paudel, Shravani Chitineni, et al.
Arthritis Care & Research|May 11, 2021
Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item ReductionSara K Tedeschi, Tristan Pascart, Augustin Latourte, et al.
Annals of the Rheumatic Diseases|July 26, 2023
The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition diseaseAbhishek Abhishek, Sara K Tedeschi, Tristan Pascart, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 26, 2023
The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition DiseaseAbhishek Abhishek, Sara K Tedeschi, Tristan Pascart, et al.
Pageof 5